Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03563248 · ClinicalTrials.gov registry record · Phase 2
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
- 10
- Study locations
NCT03563248 is a Phase 2 study of Pancreatic Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 168 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (57% lower). The trial reports 10 study locations across 6 states.
The verdict
NCT03563248, a Phase 2 study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
- 10
- Study locations
Study Summary
This research study is studying a combination of interventions as a possible treatment for pancreatic tumor. The interventions involved in this study are: * FOLFIRINOX which is made up of 4 different drugs: * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin * Losartan * Nivolumab * Radiation Therapy * Surgery
Conditions Studied
Interventions
- DRUG Nivolumab
- PROCEDURE Surgery
- DRUG Losartan
- RADIATION SBRT
- DRUG FOLFIRINOX
Study Locations (10)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
- Newton Wellesley Hospital - Newton
Colorado
- University of Colorado Cancer Center - Aurora
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Maryland
- The Johns Hopkins Hospital - Baltimore
New York
- New York University Langone Medical Center - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2018-08-10 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03563248
The ClinicalTrials.gov registry entry for NCT03563248 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (57% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.
NCT03563248 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Massachusetts, Colorado, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03563248 about?
NCT03563248 is a clinical study titled "Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer". This research study is studying a combination of interventions as a possible treatment for pancreatic tumor. The interventions involved in this study are: * FOLFIRINOX which is made up of 4 different drugs: * 5-Fluorouracil (5-FU) * Oxaliplatin * Irinotecan * Leucovorin * Losartan * Nivol...
What is the current status of trial NCT03563248?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2018-08-10. Estimated completion is 2027-04.
What conditions does trial NCT03563248 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT03563248?
The interventions under investigation include: Nivolumab (DRUG), Surgery (PROCEDURE), Losartan (DRUG), SBRT (RADIATION), FOLFIRINOX (DRUG).
Who is sponsoring clinical trial NCT03563248?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03563248 being conducted?
This trial has 10 study locations across Colorado, District of Columbia, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.